The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD), a public-private partnership to identify drivers of common metabolic diseases, has released a Funding Opportunity Announcement (FOA) for its cycle 3 Opportunity Pool. This Opportunity Pool, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supports research aligned with the AMP-CMD consortium goals of supporting the generation and analysis of genetic association results, epigenomic annotations, and functional studies, and the representation of these results in the Common Metabolic Diseases Knowledge Portal CMDKP).
This application cycle focuses on novel approaches to identify the functional mechanisms underlying associations for cardiometabolic diseases and related traits. Topics of interest include, but are not limited to:
- Novel computational tools to better identify effector transcripts
- Improved cell models to analyze gene function
- Improved cell assays to analyze effector transcript functions in cardiometabolic cell types (adipocytes, myocytes, etc.)
We welcome applications from both within and outside of the AMP CMD consortium. Proposals are due on Tuesday, September 5th, 2023. Please refer to the Funding Opportunity Announcement and the Opportunity Pool Handbook for the application procedure and more details.
Please send an email to amp-cmd-opportunity-pool(at)broadinstitute.org if you have any questions.
